For the Inventor, By the Inventor

Enter assignee name

Foster City, CA, United States of America

Neupharma, Inc.

USPTO Granted Patents = 41

% Expired Patents = 4.9

EPO Patents = 14

Forward Citations = 220

Loading Chart...

Loading Chart...

3 inventors (with patents filed for the assignee):

Xiangping Qian (41 out of 92 patents)

Yong-Liang Zhu (29 out of 36 patents)

Yong-Iiang Zhu (1 out of 1 patent)

4. Yongliang Zhu (0 patent)

Core Competencies:

Quinazolines

Kinase Inhibitors

Pharmaceutical Compositions

Cancer Treatment

Chemical Entities

B-RAF Kinase

Benzenesulfonamide

Steroids

41 patents: Sort by Forward Citations

1. 12403145 - Substituted quinazolines for inhibiting kinase activity (2025-09-02),

2. 12018002 - Certain chemical entities, compositions, and methods (2024-06-25),

3. 11865120 - Substituted quinazolines for inhibiting kinase activity (2024-01-09),

4. 11465975 - Certain chemical entities, compositions, and methods (2022-10-11),

5. 11325940 - Certain chemical entities, compositions, and methods (2022-05-10),

6. 11304957 - Substituted quinazolines for inhibiting kinase activity (2022-04-19),

7. 11208388 - Certain chemical entities, compositions, and methods (2021-12-28),

8. 10947201 - Certain chemical entities, compositions, and methods (2021-03-16),

9. 10766920 - Certain chemical entities, compositions, and methods (2020-09-08),

10. 10759766 - Certain chemical entities, compositions, and methods (2020-09-01),

11. 10653701 - Substituted quinazolines for inhibiting kinase activity (2020-05-19),

12. 10590106 - Certain chemical entities, compositions, and methods (2020-03-17),

13. 10561652 - Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer (2020-02-18),

14. 10544106 - Certain chemical entities, compositions, and methods (2020-01-28),

15. 10487108 - Certain steroids and methods for using the same in the treatment of cancer (2019-11-26),

Neupharma, Inc., based in Foster City, CA, specializes in the development of innovative pharmaceutical solutions targeting cancer treatment. The company focuses on advanced chemical entities, including substituted quinazolines, kinase inhibitors, and benzenesulfonamide derivatives, which are integral to its therapeutic strategies. Neupharma's research encompasses a range of chemical compounds, including quinoxaline and steroid derivatives, aimed at enhancing treatment efficacy and patient outcomes in oncology.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Neupharma, Inc.

41 Patents

#12 in Foster City, CA

#1,985 in California

#8,427 in US

#16,669 in the World

Foster City, CA, United States of America

Neupharma, Inc.

Forward Citations = 220

3 inventors:

Xiangping Qian (41 out of 92 patents)

Yong-Liang Zhu (29 out of 36 patents)

Yong-Iiang Zhu (1 out of 1 patent)

4. Yongliang Zhu (0 patent)

Please report any incorrect information to [email protected]

Loading…